Concepts (203)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tularemia | 2 | 2021 | 115 | 1.190 |
Why?
|
| Francisella tularensis | 2 | 2021 | 116 | 1.170 |
Why?
|
| Cultural Evolution | 2 | 2018 | 2 | 1.140 |
Why?
|
| Communicable Diseases, Emerging | 2 | 2018 | 14 | 1.100 |
Why?
|
| Antigen Presentation | 4 | 2015 | 59 | 1.010 |
Why?
|
| T-Lymphocyte Subsets | 5 | 2016 | 91 | 0.990 |
Why?
|
| Infection Control | 2 | 2024 | 17 | 0.950 |
Why?
|
| Histocompatibility Antigens Class I | 3 | 2015 | 32 | 0.900 |
Why?
|
| Archaeology | 2 | 2018 | 4 | 0.720 |
Why?
|
| Hospitalization | 1 | 2024 | 482 | 0.670 |
Why?
|
| Sepsis | 1 | 2021 | 90 | 0.640 |
Why?
|
| Vaccinia virus | 2 | 2015 | 12 | 0.590 |
Why?
|
| Cytokines | 2 | 2021 | 661 | 0.560 |
Why?
|
| Social Change | 1 | 2017 | 19 | 0.560 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 3 | 2016 | 17 | 0.520 |
Why?
|
| Antigens, Bacterial | 3 | 2024 | 144 | 0.500 |
Why?
|
| Cultural Diversity | 1 | 2017 | 187 | 0.490 |
Why?
|
| Lymphocyte Activation | 4 | 2016 | 244 | 0.440 |
Why?
|
| T-Lymphocytes | 3 | 2013 | 378 | 0.430 |
Why?
|
| Mycobacterium tuberculosis | 3 | 2024 | 106 | 0.420 |
Why?
|
| Peptides | 2 | 2015 | 357 | 0.410 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2013 | 31 | 0.400 |
Why?
|
| Antigen-Presenting Cells | 1 | 2013 | 31 | 0.400 |
Why?
|
| Granzymes | 1 | 2013 | 19 | 0.400 |
Why?
|
| Mycobacterium | 1 | 2013 | 16 | 0.390 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2013 | 45 | 0.390 |
Why?
|
| Mice, Inbred C57BL | 4 | 2024 | 1804 | 0.380 |
Why?
|
| Dermatomyositis | 2 | 2024 | 9 | 0.350 |
Why?
|
| Antirheumatic Agents | 2 | 2024 | 35 | 0.340 |
Why?
|
| Isoantigens | 1 | 2010 | 5 | 0.340 |
Why?
|
| Transplantation Tolerance | 1 | 2010 | 3 | 0.340 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2010 | 10 | 0.340 |
Why?
|
| Graft vs Host Disease | 1 | 2010 | 15 | 0.340 |
Why?
|
| Monocytes | 1 | 2013 | 275 | 0.330 |
Why?
|
| Hemiterpenes | 2 | 2016 | 7 | 0.330 |
Why?
|
| Graft Rejection | 1 | 2010 | 43 | 0.330 |
Why?
|
| Graft Survival | 1 | 2010 | 47 | 0.330 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2010 | 66 | 0.320 |
Why?
|
| Organophosphorus Compounds | 2 | 2016 | 37 | 0.320 |
Why?
|
| Obesity | 1 | 2018 | 1131 | 0.320 |
Why?
|
| Leptin | 3 | 2022 | 118 | 0.320 |
Why?
|
| Mycobacterium bovis | 1 | 2008 | 14 | 0.300 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2008 | 21 | 0.290 |
Why?
|
| Macrophages | 1 | 2013 | 515 | 0.290 |
Why?
|
| Tuberculosis | 3 | 2024 | 76 | 0.280 |
Why?
|
| Nicotine | 2 | 2022 | 290 | 0.270 |
Why?
|
| Animals | 12 | 2024 | 16695 | 0.260 |
Why?
|
| Nanoparticles | 2 | 2024 | 449 | 0.260 |
Why?
|
| Mice | 7 | 2024 | 6490 | 0.240 |
Why?
|
| Humans | 15 | 2024 | 42163 | 0.240 |
Why?
|
| Amino Acid Sequence | 3 | 2015 | 1188 | 0.240 |
Why?
|
| Molecular Sequence Data | 3 | 2015 | 1559 | 0.240 |
Why?
|
| Consensus | 1 | 2024 | 53 | 0.220 |
Why?
|
| Tuberculosis Vaccines | 1 | 2024 | 3 | 0.220 |
Why?
|
| Administration, Intranasal | 1 | 2024 | 89 | 0.210 |
Why?
|
| Texas | 1 | 2024 | 428 | 0.190 |
Why?
|
| Proteomics | 2 | 2015 | 363 | 0.180 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2022 | 126 | 0.170 |
Why?
|
| Cell Line | 3 | 2015 | 1416 | 0.170 |
Why?
|
| Alginates | 1 | 2020 | 19 | 0.170 |
Why?
|
| Zinc Oxide | 1 | 2020 | 25 | 0.160 |
Why?
|
| Hydrogels | 1 | 2020 | 55 | 0.160 |
Why?
|
| Wound Healing | 1 | 2020 | 82 | 0.160 |
Why?
|
| Lipopolysaccharides | 1 | 2021 | 235 | 0.150 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2019 | 14 | 0.150 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2019 | 28 | 0.150 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2019 | 23 | 0.150 |
Why?
|
| Ventral Tegmental Area | 1 | 2019 | 47 | 0.150 |
Why?
|
| Disease Progression | 1 | 2021 | 661 | 0.140 |
Why?
|
| History, Ancient | 1 | 2017 | 15 | 0.140 |
Why?
|
| Nicotinic Agonists | 1 | 2019 | 87 | 0.140 |
Why?
|
| Nucleus Accumbens | 1 | 2019 | 99 | 0.140 |
Why?
|
| Geography | 1 | 2017 | 107 | 0.140 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2019 | 126 | 0.130 |
Why?
|
| Exanthema | 1 | 2016 | 12 | 0.130 |
Why?
|
| Insulin | 1 | 2019 | 255 | 0.130 |
Why?
|
| Glycolipids | 1 | 2016 | 9 | 0.130 |
Why?
|
| Research | 1 | 2018 | 177 | 0.130 |
Why?
|
| Adolescent | 2 | 2024 | 5950 | 0.130 |
Why?
|
| Female | 6 | 2024 | 24018 | 0.130 |
Why?
|
| Models, Theoretical | 1 | 2017 | 230 | 0.120 |
Why?
|
| CD40 Ligand | 1 | 2015 | 9 | 0.120 |
Why?
|
| Epitopes | 2 | 2013 | 155 | 0.120 |
Why?
|
| Oncogenes | 1 | 2015 | 44 | 0.120 |
Why?
|
| Disease Models, Animal | 1 | 2021 | 1554 | 0.110 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2016 | 184 | 0.110 |
Why?
|
| Algorithms | 1 | 2017 | 508 | 0.110 |
Why?
|
| Phylogeny | 1 | 2018 | 740 | 0.110 |
Why?
|
| Young Adult | 1 | 2024 | 4936 | 0.100 |
Why?
|
| United States | 1 | 2024 | 5072 | 0.100 |
Why?
|
| Male | 6 | 2024 | 22779 | 0.100 |
Why?
|
| Leucyl Aminopeptidase | 1 | 2013 | 4 | 0.100 |
Why?
|
| Antigens, Ly | 1 | 2013 | 8 | 0.100 |
Why?
|
| Antigens | 1 | 2013 | 58 | 0.100 |
Why?
|
| Time Factors | 1 | 2017 | 1848 | 0.100 |
Why?
|
| Sequence Analysis, Protein | 1 | 2013 | 51 | 0.100 |
Why?
|
| Neutralization Tests | 1 | 2013 | 55 | 0.100 |
Why?
|
| Aged | 2 | 2024 | 7982 | 0.100 |
Why?
|
| Mice, Knockout | 2 | 2013 | 1010 | 0.100 |
Why?
|
| Gene Knockdown Techniques | 1 | 2013 | 188 | 0.090 |
Why?
|
| Natural Killer T-Cells | 1 | 2011 | 11 | 0.090 |
Why?
|
| Interleukin-15 | 1 | 2011 | 13 | 0.090 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2013 | 181 | 0.090 |
Why?
|
| Gene Expression Regulation, Bacterial | 1 | 2013 | 168 | 0.090 |
Why?
|
| Cell Differentiation | 2 | 2011 | 633 | 0.090 |
Why?
|
| Rheumatology | 2 | 2024 | 17 | 0.090 |
Why?
|
| Host-Pathogen Interactions | 1 | 2013 | 203 | 0.090 |
Why?
|
| Peptide Fragments | 1 | 2013 | 301 | 0.090 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2013 | 230 | 0.090 |
Why?
|
| Influenza Vaccines | 1 | 2011 | 55 | 0.080 |
Why?
|
| Transplantation, Homologous | 1 | 2010 | 37 | 0.080 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2013 | 379 | 0.080 |
Why?
|
| RNA, Small Interfering | 1 | 2013 | 436 | 0.080 |
Why?
|
| Middle Aged | 2 | 2024 | 11819 | 0.080 |
Why?
|
| Influenza, Human | 1 | 2011 | 90 | 0.080 |
Why?
|
| Th2 Cells | 1 | 2010 | 63 | 0.080 |
Why?
|
| Homeostasis | 1 | 2011 | 193 | 0.080 |
Why?
|
| Th1 Cells | 1 | 2010 | 97 | 0.080 |
Why?
|
| Rats, Wistar | 2 | 2022 | 282 | 0.080 |
Why?
|
| Membrane Proteins | 1 | 2013 | 548 | 0.080 |
Why?
|
| Adult | 2 | 2024 | 13458 | 0.080 |
Why?
|
| Protein Conformation | 1 | 2010 | 420 | 0.080 |
Why?
|
| Antibodies, Viral | 1 | 2011 | 295 | 0.080 |
Why?
|
| Ligands | 1 | 2010 | 387 | 0.080 |
Why?
|
| Clone Cells | 1 | 2008 | 50 | 0.070 |
Why?
|
| Structure-Activity Relationship | 1 | 2010 | 491 | 0.070 |
Why?
|
| Cells, Cultured | 1 | 2013 | 1617 | 0.070 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2024 | 276 | 0.070 |
Why?
|
| Immunity, Innate | 1 | 2008 | 168 | 0.070 |
Why?
|
| Models, Molecular | 1 | 2010 | 875 | 0.060 |
Why?
|
| Fomites | 1 | 2005 | 3 | 0.060 |
Why?
|
| Caliciviridae Infections | 1 | 2005 | 8 | 0.060 |
Why?
|
| Norovirus | 1 | 2005 | 15 | 0.060 |
Why?
|
| Gastroenteritis | 1 | 2005 | 18 | 0.060 |
Why?
|
| Inflammation | 1 | 2010 | 729 | 0.060 |
Why?
|
| Nursing Homes | 1 | 2005 | 63 | 0.060 |
Why?
|
| Acyltransferases | 1 | 2024 | 21 | 0.050 |
Why?
|
| Disease Outbreaks | 1 | 2005 | 169 | 0.050 |
Why?
|
| Immunity, Mucosal | 1 | 2024 | 52 | 0.050 |
Why?
|
| Adjuvants, Immunologic | 1 | 2024 | 117 | 0.050 |
Why?
|
| Cell Survival | 2 | 2020 | 934 | 0.050 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2024 | 293 | 0.050 |
Why?
|
| Rats | 2 | 2022 | 3701 | 0.050 |
Why?
|
| Child | 2 | 2024 | 3381 | 0.050 |
Why?
|
| Biological Products | 1 | 2024 | 91 | 0.050 |
Why?
|
| Corticosterone | 1 | 2022 | 89 | 0.050 |
Why?
|
| Severity of Illness Index | 1 | 2024 | 708 | 0.050 |
Why?
|
| Lung | 1 | 2024 | 484 | 0.040 |
Why?
|
| Signal Transduction | 1 | 2010 | 2111 | 0.040 |
Why?
|
| Prefrontal Cortex | 1 | 2022 | 160 | 0.040 |
Why?
|
| Ethanol | 1 | 2022 | 221 | 0.040 |
Why?
|
| Mice, Transgenic | 2 | 2013 | 658 | 0.040 |
Why?
|
| Treatment Outcome | 1 | 2024 | 1586 | 0.040 |
Why?
|
| Flow Cytometry | 2 | 2011 | 411 | 0.040 |
Why?
|
| Bacterial Proteins | 1 | 2024 | 580 | 0.040 |
Why?
|
| Drinking Behavior | 1 | 2019 | 18 | 0.040 |
Why?
|
| Fibroblasts | 1 | 2020 | 278 | 0.040 |
Why?
|
| Self Administration | 1 | 2019 | 67 | 0.040 |
Why?
|
| Body Weight | 1 | 2019 | 428 | 0.030 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2016 | 17 | 0.030 |
Why?
|
| Methotrexate | 1 | 2016 | 22 | 0.030 |
Why?
|
| Methylglucosides | 1 | 2016 | 1 | 0.030 |
Why?
|
| Adaptive Immunity | 1 | 2016 | 32 | 0.030 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2016 | 62 | 0.030 |
Why?
|
| Water | 1 | 2019 | 314 | 0.030 |
Why?
|
| Behavior, Animal | 1 | 2019 | 369 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2016 | 233 | 0.030 |
Why?
|
| Polysaccharides | 1 | 2016 | 70 | 0.030 |
Why?
|
| Immunologic Memory | 1 | 2015 | 41 | 0.030 |
Why?
|
| Feeding Behavior | 1 | 2019 | 461 | 0.030 |
Why?
|
| Dendritic Cells | 1 | 2015 | 130 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2015 | 246 | 0.030 |
Why?
|
| Immunodominant Epitopes | 1 | 2013 | 28 | 0.030 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2013 | 59 | 0.020 |
Why?
|
| Hela Cells | 1 | 2013 | 370 | 0.020 |
Why?
|
| bcl-X Protein | 1 | 2011 | 27 | 0.020 |
Why?
|
| Lymphocyte Count | 1 | 2011 | 47 | 0.020 |
Why?
|
| Hemagglutination Inhibition Tests | 1 | 2011 | 8 | 0.020 |
Why?
|
| Vaccines, Inactivated | 1 | 2011 | 16 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2013 | 279 | 0.020 |
Why?
|
| Immunization, Secondary | 1 | 2011 | 15 | 0.020 |
Why?
|
| Vaccines, Attenuated | 1 | 2011 | 75 | 0.020 |
Why?
|
| Thymus Gland | 1 | 2011 | 74 | 0.020 |
Why?
|
| Cell Lineage | 1 | 2011 | 104 | 0.020 |
Why?
|
| Spleen | 1 | 2011 | 199 | 0.020 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2010 | 138 | 0.020 |
Why?
|
| Phenotype | 1 | 2013 | 774 | 0.020 |
Why?
|
| Cell Separation | 1 | 2010 | 94 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2010 | 181 | 0.020 |
Why?
|
| Protein Kinase C | 1 | 2010 | 124 | 0.020 |
Why?
|
| Vaccination | 1 | 2011 | 332 | 0.020 |
Why?
|
| Transfection | 1 | 2010 | 526 | 0.020 |
Why?
|
| Liver | 1 | 2011 | 503 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2010 | 297 | 0.020 |
Why?
|
| Infant | 1 | 2011 | 1143 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2011 | 1516 | 0.020 |
Why?
|
| Equipment Contamination | 1 | 2005 | 6 | 0.020 |
Why?
|
| Philadelphia | 1 | 2005 | 20 | 0.020 |
Why?
|
| Occupational Diseases | 1 | 2005 | 53 | 0.010 |
Why?
|
| Long-Term Care | 1 | 2005 | 55 | 0.010 |
Why?
|
| Veterans | 1 | 2005 | 203 | 0.010 |
Why?
|
| Health Personnel | 1 | 2005 | 262 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2005 | 2803 | 0.010 |
Why?
|